On March 16, 2022, the Court of Appeals for the Federal Circuit denied Biogen’s petition for en banc review in Biogen International GmbH et al. v. Mylan Pharmaceuticals Inc. ("Petition Denial"), in which a Federal Circuit...more
3/24/2022
/ Appeals ,
Denial of Rehearing ,
Dissenting Opinions ,
En Banc Review ,
Mylan Pharmaceuticals ,
Patents ,
Petition for Writ of Certiorari ,
Pharmaceutical Patents ,
SCOTUS ,
Validity ,
Written Descriptions